Healthcare firm Accolade rises on $621 mln take-private offer

Accolade

08/01/2025 14:22

** Shares of healthcare company Accolade  ACCD.O  more than
double to $6.90 premarket 
    ** ACCD says it has entered into an agreement where
Transcarent will acquire it for $7.03 per share in cash,
representing an equity value of about $621 mln
    ** Transaction is expected to close in Q2 2025; upon
completion, ACCD will become privately held company
    ** Deal represents a premium of ~110% over ACCD's last
closing price  
    ** Transcarent uses generative AI to provide health
information, while also providing personalized health guidance
and on-demand care
    ** ACCD provides personalized, technology-enabled solutions
to help people understand and utilize healthcare system and
workplace benefits
    ** Deal will "create a more personalized healthcare
experience for people while improving outcomes and driving down
costs," ACCD says
    ** Up to last close, ACCD had fallen 69.5% in the past 12
months

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))